Armonica Technologies
Benjamin Delatte, PhD, currently serves as the Director and Head of Epigenetics Research at Armonica Technologies, Inc. since September 2024, and is also an Editor for Frontiers in Genetics. With experience as a Journal Editor for Biochemical Genetics at Springer Nature since 2018, Benjamin previously held the position of Associate Director of R&D and Group Leader for Epigenomics/Epitranscriptomics at Active Motif until September 2024. During tenure at Active Motif, responsibilities included overseeing assay development and managing project progress. Prior experience includes a Transformative Leadership Program Board Member role at the University of California, Riverside and a Postdoctoral Fellowship at the La Jolla Institute for Immunology. Benjamin earned a PhD in Cancer Epigenetics from the Free University of Brussels.
This person is not in any teams
Armonica Technologies
Armonica Technologies is an early stage medtech company focused on developing its proprietary long-read DNA sequencing technology for precision medicine applications. Armonica’s technology uses proprietary nanochannels to deliver single DNA molecules through nanopores for optical readout by Raman spectroscopy. Armonica’s approach will lead to faster, more thorough, and more accurate genomic analysis than is currently available, without the need for library preparation.